Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
This randomized phase III trial studies armodafinil to see how well it works in reducing
 cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve
 fatigue in patients with high grade glioma.
Patients experiencing fatigue related to cancer will be asked to take part in this study.
 Cancer-related fatigue is a very common symptom in patients with cancer. Patients will
 receive armodafinil or placebo. Please see the "Arms" section for more details regarding the
 treatment assignments. The primary objective of this study is to determine preliminary
 efficacy measured by patient reported fatigue Brief Fatigue Inventory (BFI) at 8 weeks of two
 doses (150 mg and 250 mg) of armodafinil in treating moderate fatigue compared to placebo in
 patients with high grade glioma.

 The secondary objectives of the study are listed below.

 1. To evaluate the tolerability at 8 weeks of 150 mg and 250 mg armodafinil in this patient
 population.

 2. To assess the effect of armodafinil at 8 weeks on cognitive function in patients with
 high grade glioma.

 3. To assess the impact of armodafinil on global quality of life and other fatigue
 endpoints in this patient population with high grade glioma.

 4. Explore the correlation between the BFI, Patient-Reported Outcomes Measurement
 Information System (PROMIS), and Patient-Reported Outcomes version of the Common
 Terminology Criteria for Adverse Events (PRO-CTCAE) measures, as well as, the
 relationship of fatigue and cognitive difficulties.

 Patients will receive armodafinil or placebo for a total of 8 weeks.
Inclusion Criteria:

 -  Diagnosed with glioblastoma, gliosarcoma, small cell or large cell glioblastoma,
 glioblastoma with oligo features, glioblastoma with primitive neuroectodermal
 tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic
 oligodendroglioma, or anaplastic oligoastrocytoma who are clinically stable and have
 completed radiation therapy (excluding stereotactic radiosurgery) > 21 days and =< 24
 months prior to enrollment; NOTE: clinical stability will be defined as a stable or
 improved Karnofsky performance status (KPS) compared to the prior month

 -  >= 6 score on the worst fatigue question of the BFI (Brief Fatigue Inventory, question
 3); it is not required for the patient to complete the entire BFI to meet this
 criterion

 -  Undergone surgery (gross total or subtotal resection) or biopsy and will have been
 treated with concurrent radiation therapy and chemotherapy as standard of care for
 glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with
 oligo features, glioblastoma with primitive neuroectodermal tumor-like components
 (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or
 anaplastic oligoastrocytoma patients; Note: radiation must be completed, but
 chemotherapy is allowed; patients who are currently using Optune device will be
 eligible to participate in this trial

 -  Negative serum pregnancy test done =< 7 days prior to registration only for women
 determined to be of childbearing potential by their treating physician

 -  Ability to complete questionnaire(s) by themselves or with assistance

 -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2 or 3

 -  Provide informed written consent

 -  Willing to return to enrolling institution for follow-up (during the Active Monitoring
 Phase of the study)

 -  Stable dose of corticosteroid >= 14 days prior to registration